Related references
Note: Only part of the references are listed.RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Kristoffer W. Brudvik et al.
ANNALS OF SURGERY (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics
Maliha Khan et al.
CLINICAL COLORECTAL CANCER (2018)
Landscape of Tumor Mutation Load, Mismatch RepairDeficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Mohamed E. Salem et al.
MOLECULAR CANCER RESEARCH (2018)
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
Ari Vanderwalde et al.
CANCER MEDICINE (2018)
Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles
Robin Imperial et al.
MOLECULAR CANCER (2018)
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kevin R. Kelly et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
Mohamed E. Salem et al.
ONCOTARGET (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
Filippo Pietrantonio et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
Jan Franko et al.
LANCET ONCOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
Wafik S. El-Deiry et al.
CANCER BIOLOGY & THERAPY (2015)
Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review
T. R. van Oudheusden et al.
EJSO (2015)
Self-Expanding Metallic Stents Versus Surgical Intervention as Palliative Therapy for Obstructive Colorectal Cancer: A Meta-analysis
Hidena Takahashi et al.
WORLD JOURNAL OF SURGERY (2015)
RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases
Yoshihiro Mise et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Metastatic pattern in colorectal cancer is strongly influenced by histological subtype
N. Hugen et al.
ANNALS OF ONCOLOGY (2014)
KRAS Mutation Influences Recurrence Patterns in Patients Undergoing Hepatic Resection of Colorectal Metastases
Nancy E. Kemeny et al.
CANCER (2014)
Exomics and immunogenics Bridging mutational load and immune checkpoints efficacy
Stephane Champiat et al.
ONCOIMMUNOLOGY (2014)
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
P. Li et al.
BRITISH JOURNAL OF CANCER (2013)
Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms
G. Nishikawa et al.
BRITISH JOURNAL OF CANCER (2013)
Incidence and Prognostic Impact of KRAS and BRAF Mutation in Patients Undergoing Liver Surgery for Colorectal Metastases
Georgios Karagkounis et al.
CANCER (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841
Jan Franko et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Gene Expression Profiling of Peritoneal Metastases from Appendiceal and Colon Cancer Demonstrates Unique Biologic Signatures and Predicts Patient Outcomes
Edward A. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2012)
Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer
Ben Tran et al.
CANCER (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy
Chiara Arienti et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas
Toru Furukawa et al.
SCIENTIFIC REPORTS (2011)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion Versus Systemic Chemotherapy Alone for Colorectal Peritoneal Carcinomatosis
Jan Franko et al.
CANCER (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
V. Catalano et al.
BRITISH JOURNAL OF CANCER (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer
Vic J. Verwaal et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
Salvatore Artale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer
Lucy K. Helyer et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Peritoneal carcinomatosis of colorectal origin - Incidence and current treatment strategies
MJ Koppe et al.
ANNALS OF SURGERY (2006)
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab
Peter S. Yoo et al.
CLINICAL COLORECTAL CANCER (2006)
Clinical significance of signet ring cell rectal carcinoma
JS Chen et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2004)
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
VJ Verwaal et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer
SL Blair et al.
ANNALS OF SURGICAL ONCOLOGY (2001)
Share Paper
